Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal
Authors
Keywords
-
Journal
AIDS
Volume 36, Issue 1, Pages 75-82
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-09-30
DOI
10.1097/qad.0000000000003091
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sensing of HIV-1 by TLR8 activates human T cells and reverses latency
- (2020) Hany Zekaria Meås et al. Nature Communications
- FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation
- (2020) Jun Jacob Hu et al. NATURE IMMUNOLOGY
- Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study
- (2019) John K Yue et al. LANCET NEUROLOGY
- Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency
- (2017) Nancie M. Archin et al. JOURNAL OF CLINICAL INVESTIGATION
- Fluid biomarkers for mild traumatic brain injury and related conditions
- (2016) Henrik Zetterberg et al. Nature Reviews Neurology
- In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection
- (2016) Perry Tsai et al. Retrovirology
- Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
- (2016) Magnus Gisslén et al. EBioMedicine
- Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations
- (2015) Gregory M. Laird et al. JOURNAL OF CLINICAL INVESTIGATION
- The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
- (2015) Ole S. Søgaard et al. PLoS Pathogens
- Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
- (2015) Julian H Elliott et al. Lancet HIV
- New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo
- (2014) C Korin Bullen et al. NATURE MEDICINE
- Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
- (2014) Julian H. Elliott et al. PLoS Pathogens
- Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
- (2014) Thomas A Rasmussen et al. Lancet HIV
- A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy
- (2013) A. M. Spivak et al. CLINICAL INFECTIOUS DISEASES
- Phosphorylation of CDK9 at Ser175 Enhances HIV Transcription and Is a Marker of Activated P-TEFb in CD4+ T Lymphocytes
- (2013) Uri R. Mbonye et al. PLoS Pathogens
- The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γ
- (2012) Sadayuki Hashioka et al. Journal of Neuroinflammation
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search